Inadequate function of this transporter has been described in several cancer types, including esophageal cancer [13,16,33,34,35,36,37]; therefore, NHE-1 emerged as a potential target in anti-cancer therapy [37,38]. The gene discussed is SLC9A1; the disease is cancer.